FY2027 EPS Forecast for IDEAYA Biosciences Raised by Analyst

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Stock analysts at Leerink Partnrs upped their FY2027 earnings estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Monday, October 20th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($4.00) per share for the year, up from their previous estimate of ($4.04). The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share.

Other equities analysts have also recently issued reports about the stock. Citigroup reiterated a “buy” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. Mizuho upped their target price on shares of IDEAYA Biosciences from $43.00 to $44.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of IDEAYA Biosciences in a research note on Tuesday, September 9th. The Goldman Sachs Group upped their target price on shares of IDEAYA Biosciences from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Oppenheimer set a $36.00 target price on shares of IDEAYA Biosciences and gave the company an “outperform” rating in a research note on Monday, September 8th. Fourteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, IDEAYA Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $44.13.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA opened at $29.18 on Thursday. The stock has a market cap of $2.56 billion, a P/E ratio of -7.70 and a beta of 0.14. IDEAYA Biosciences has a one year low of $13.45 and a one year high of $32.67. The company has a fifty day moving average price of $26.20 and a 200 day moving average price of $22.64.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The company had revenue of $6.00 million for the quarter, compared to analyst estimates of $3.48 million. The company’s revenue for the quarter was up NaN% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.68) earnings per share.

Institutional Investors Weigh In On IDEAYA Biosciences

Hedge funds have recently made changes to their positions in the company. CWM LLC grew its holdings in IDEAYA Biosciences by 325.7% during the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after acquiring an additional 1,814 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after acquiring an additional 1,546 shares during the last quarter. Signaturefd LLC grew its holdings in IDEAYA Biosciences by 374.8% during the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after acquiring an additional 2,271 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in IDEAYA Biosciences during the 2nd quarter worth about $61,000. Finally, Daiwa Securities Group Inc. grew its holdings in IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after acquiring an additional 436 shares during the last quarter. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.